FIELD: medicine.
SUBSTANCE: the invention relates to medicine, in particular, to haematology, and can be used for stimulation of myelogenesis. Pegylated hyaluronidase is administered with the dosage of 50 action units/kg 1 time a day for two days, additionally a medication containing D-glucuronic acid is intravenously administered once with the dosage of 2 mg/kg.
EFFECT: accelerated regenerative processes of haemopoietic tissues with additional administration of low doses of D-glucuronic acid, caused by its regulatory influence on hyaluronic acid metabolism of blood-forming precursors.
3 tbl, 1 ex, 1 dwg
| Title | Year | Author | Number | 
|---|---|---|---|
| METHOD OF MYELOPOIESIS STIMULATION | 2007 | 
 | RU2336899C1 | 
| HEMOSTIMULANT AND EXCITANT AND METHOD FOR HEMOPOIESIS STIMULATION | 2009 | 
 | RU2414926C1 | 
| METHOD OF MYELOPOIESIS STIMULATION | 2008 | 
 | RU2366452C1 | 
| HAEMOSTIMULATING AGENT | 2013 | 
 | RU2535021C1 | 
| HEMOSTIMULATING MEDICATION | 2012 | 
 | RU2505308C1 | 
| METHOD FOR PREPARING CELL TRANSPLANTATION MATERIAL IN MYELOSUPPRESSION | 2008 | 
 | RU2392947C1 | 
| METHOD OF DETERMINING EFFICACY OF HAEMOSTIMULATORS IN CYTOSTATIC MYELOSUPPRESSION | 2009 | 
 | RU2421720C2 | 
| HEMOSTIMULATING AGENT | 2013 | 
 | RU2514648C1 | 
| METHOD OF STIMULATION IN VITRO PLURIPOTENT HEMOPOETIC STEM CELLS | 2010 | 
 | RU2439147C1 | 
| MEDICATION POSSESSING HAEMOSTIMULATING, ANTIMUTAGENIC, ANTITUMOUR, CEREBROPROTECTIVE, ANTIHYPOXIC, NOOTROPIC, ANXIOLYTIC AND ANTINEUROTIC ACTION | 2010 | 
 | RU2438691C1 | 
Authors
Dates
2012-02-20—Published
2010-10-11—Filed